VA-DXC-TECHNOLOGY
18.3.2020 14:02:17 CET | Business Wire | Press release
DXC Technology (NYSE: DXC) today introduced an advanced Patient-Centered Care solution, a customizable and personalized-health offering that gives healthcare providers the technology to meet the high expectations of today’s patients — without sacrificing cost containment and clinician satisfaction.
The healthcare industry is experiencing a value-based shift of epic proportions, driven by key external trends like an aging population; the proliferation of chronic diseases; rising healthcare costs; staffing shortages; and digital citizenship creating more informed patients. To elevate the patient experience, improve individual outcomes and create a healthier population, healthcare leaders are seeking new business and integrated care models that merge healthcare and life sciences while empowering patients and providers alike.
To help solve these challenges, DXC Patient-Centered Care provides advanced patient-engagement tools that offer convenient care from anywhere, via phone or tablet, at an affordable price. Backed by DXC’s interoperability, analytics and security products, the solution enables providers to access a continuous stream of patient-care data, helping them put the patient first throughout the continuum of care.
“In the age of ‘Dr. Google’ and same-day Amazon deliveries, patients are increasingly more demanding. They will no longer tolerate half-day waits for discharge instructions that could be delivered in seconds via a chatbot, or receive test results by snail mail when they could be viewed immediately on a mobile app. They expect better value and engagement from caregivers, driving the industry to move from traditional care-delivery models toward a patient-centered journey of care,” said Andrea Fiumicelli, vice president and general manager, Healthcare and Life Sciences , DXC Technology. “Our new Patient-Centered Care solution combines DXC’s industry expertise and leading healthcare technology to equip providers with custom-built, next-generation and coordinated care solutions.”
“The future of connected healthcare is centered around collaboration and care, and today’s busy providers need to find innovative ways to connect with their patients within and beyond the walls of a hospital or clinic,” said Dr. Michael Dahlweid, who recently joined DXC as its new global chief medical officer. “Our goal is to enable care teams to share health information across multiple systems, channels, practices and infrastructures, and aggregate it into a secure, consolidated view of the patient’s history of care. This persona-based access to real-time health data will allow clinicians to make the best possible decisions for their patients’ treatment. With speed, scale, flexibility and continuous innovation, DXC Technology prepares traditional healthcare organizations to become major digital-health enablers.”
The DXC Healthcare Portfolio
Patient-Centered Care is the newest solution in DXC’s extensive healthcare portfolio that is transforming the healthcare industry. The portfolio also includes:
- DXC Open Health Connect , a healthcare platform that helps improve healthcare outcomes by creating a connected ecosystem for patients, providers and payers.
- DXC Healthcare Cloud , a cloud-based solution that reduces complexity and risk while allowing approved parties to securely access applications and data 24/7.
- DXC Healthcare Security Services — for which DXC was recently named a leader in the Everest Group PEAK Matrix Assessment 2020 — to help healthcare providers quickly identify and respond to threats, protect data and patient privacy, and securely manage patient identities stored on-premise or in the cloud.
- DXC Health360 ™ , a cloud-based solution that enables providers and payers to personalize care experiences, deliver quality and increase customer loyalty at a lower cost.
- DXC Life Sciences solutions , which give life sciences organizations — including all 12 U.S. Fortune 500 pharmaceutical companies — the tools they need to accelerate innovation, improve operational efficiencies and reduce time to market for new therapies, devices and medicines.
About DXC Technology
DXC Technology (NYSE: DXC) helps global companies run their mission critical systems and operations while modernizing IT, optimizing data architectures, and ensuring security and scalability across public, private and hybrid clouds. With decades of driving innovation, the world’s largest companies trust DXC to deploy our enterprise technology stack to deliver new levels of performance, competitiveness and customer experiences. Learn more about the DXC story and our focus on people, customers and operational execution at www.dxc.technology .
# # #
View source version on businesswire.com: https://www.businesswire.com/news/home/20200318005372/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 17:15:00 CEST | Press release
In myelofibrosis (MF), INCA033989 delivered rapid and durable clinical benefits including meaningful spleen volume reductions, symptom improvement and anemia responses, both as a monotherapy and in combination with ruxolitinibIn essential thrombocythemia (ET), 87% of patients achieved a hematologic response, including 70% complete responses; responses were rapid (median ~2 weeks to a durable complete hematologic response) and durable (median response duration of 23 weeks)Across MF and ET, INCA033989 consistently reduced mutant CALR (mutCALR) variant allele frequency (VAF) in most evaluable patients, with reductions correlating with clinical responses and supporting its potential for disease modificationFirst-in-class mutCALR-targeted antibody shows potential to modify disease biology in both MF and ETINCA033989 demonstrated a favorable and manageable safety profile with no dose-limiting toxicities, with most patients with MF and ET continuing treatment Incyte (Nasdaq:INCY) today announ
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 12:00:00 CEST | Press release
- frontMIND study evaluating tafasitamab (Monjuvi®/Minjuvi®) in patients with previously untreated high-risk diffuse large B-cell lymphoma (DLBCL) and high-grade B-cell lymphoma (HGBL) selected for the prestigious Plenary Abstracts Session at EHA 2026 - Results showed tafasitamab and lenalidomide plus R-CHOP (Tafa-Len-R-CHOP) significantly prolonged progression-free survival (PFS), reducing risk of disease progression or death by 25% - Positive trends toward PFS benefit with Tafa-Len-R-CHOP were observed acrossprespecified subgroups, including in patients with centrally confirmed lymphoma subtypes and both cell-of-origin (COO) molecular subtypes - The frontMIND data support global regulatory applications for tafasitamab and lenalidomide in addition to R-CHOP for previously untreated DLBCL and HGBL Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified c
Charlotte Tilbury awarded CBE in the King’s Birthday Honours 202612.6.2026 23:31:00 CEST | Press release
Charlotte Tilbury CBE, sole Founder, President, Chairman and Chief Creative Officer of Charlotte Tilbury Beauty, has been awarded a Commander of the Order of the British Empire (CBE) in the King’s Birthday Honours 2026 for services to the beauty and cosmetics industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612679101/en/ Charlotte Tilbury, founder, president, chairman and chief creative officer of Charlotte Tilbury Beauty, who has been awarded a CBE (Commander of the Order of the British Empire) in 2026 for services to the beauty industry and entrepreneurship. (Photo: Charlotte Tilbury team) This honour recognises Charlotte’s contribution to leading and building Britain’s most successful global beauty brand. She has played a defining role in revolutionising the beauty industry and driving economic growth of the UK beauty sector, which has expanded from approximately £17bn in 2013 to over £31bn today. Charlotte Til
IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors12.6.2026 18:36:00 CEST | Press release
Venneman brings more than 30 years of digital transformation, AI, and enterprise technology experience as IQM prepares for its planned Nasdaq listing IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointment of Barbara Venneman to its Board of Directors. Venneman deepens the Board's expertise in digital transformation, enterprise technology commercialization, and global business scaling as IQM expands its commercial footprint worldwide. Additionally, CEO and Co-founder Jan Goetz will replace Co-founder Juha Vartiainen as the Founder representative on the IQM Board. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612650938/en/ IQM Appoints Barbara Venneman, Vanguard Board Director and Former Global Head of Deloitte Digital, to its Board of Directors Ms. Venneman joins the IQM Board of Directors following a distinguished career at the intersection of advanced technology, s
DEWA Organises Second Agentic AI Retreat at Al Shera’a, World’s Tallest, Largest and Smartest Net‑Positive Government Building12.6.2026 17:08:00 CEST | Press release
HE Saeed Mohammed Al Tayer, MD & CEO of Dubai Electricity and Water Authority (DEWA),has emphasised that DEWA deploys the latest Agentic AI technologies, in line with the vision to enhance its leading role and reinforce Dubai’s position as the city of the future. He made these remarks during the Agentic AI Executive Retreat DEWA organised at Al Shera’a, its new headquarters, which is the world’s tallest, largest and smartest net-positive government building. The event was attended by the executive leadership team and key stakeholders in digital transformation and artificial intelligence (AI), as well as representatives from SAP and McKinsey. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260612633834/en/ DEWA organises second Agentic AI Retreat at Al Shera’a, world’s tallest, largest and smartest net positive government building (Photo: AETOSWire) In his speech, Al Tayer said that DEWA is guided by directives from the wise l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
